A detailed history of Van Eck Associates Corp transactions in Biogen Inc. stock. As of the latest transaction made, Van Eck Associates Corp holds 98,937 shares of BIIB stock, worth $14.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
98,937
Previous 922,761 89.28%
Holding current value
$14.7 Million
Previous $214 Million 91.54%
% of portfolio
0.02%
Previous 0.3%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

SELL
$189.07 - $236.8 $156 Million - $195 Million
-823,824 Reduced 89.28%
98,937 $18.1 Million
Q2 2024

Jul 31, 2024

SELL
$190.52 - $236.72 $155 Million - $193 Million
-814,579 Reduced 46.89%
922,761 $214 Million
Q1 2024

Apr 30, 2024

BUY
$212.02 - $267.71 $67 Million - $84.6 Million
316,144 Added 22.24%
1,737,340 $375 Million
Q4 2023

Feb 05, 2024

BUY
$222.59 - $267.94 $51.6 Million - $62.1 Million
231,650 Added 19.47%
1,421,196 $368 Million
Q3 2023

Nov 08, 2023

BUY
$253.3 - $285.89 $59.2 Million - $66.9 Million
233,889 Added 24.47%
1,189,546 $306 Million
Q2 2023

Aug 03, 2023

BUY
$275.25 - $318.06 $40 Million - $46.2 Million
145,279 Added 17.93%
955,657 $272 Million
Q1 2023

May 03, 2023

BUY
$256.56 - $292.34 $5.85 Million - $6.67 Million
22,820 Added 2.9%
810,378 $225 Million
Q4 2022

Feb 08, 2023

SELL
$252.44 - $306.72 $32.9 Million - $40 Million
-130,428 Reduced 14.21%
787,558 $218 Million
Q3 2022

Oct 27, 2022

SELL
$194.69 - $268.46 $6.2 Million - $8.55 Million
-31,849 Reduced 3.35%
917,986 $245 Million
Q2 2022

Aug 03, 2022

BUY
$187.54 - $223.02 $2.24 Million - $2.67 Million
11,957 Added 1.27%
949,835 $194 Million
Q1 2022

May 10, 2022

BUY
$193.77 - $244.14 $26.9 Million - $33.9 Million
138,949 Added 17.39%
937,878 $198 Million
Q4 2021

Jan 26, 2022

BUY
$223.92 - $287.77 $35.6 Million - $45.7 Million
158,854 Added 24.82%
798,929 $192 Million
Q3 2021

Nov 03, 2021

BUY
$282.99 - $369.05 $12.3 Million - $16.1 Million
43,528 Added 7.3%
640,075 $181 Million
Q2 2021

Aug 10, 2021

SELL
$259.0 - $414.71 $7.12 Million - $11.4 Million
-27,497 Reduced 4.41%
596,547 $207 Million
Q1 2021

May 13, 2021

BUY
$242.95 - $284.63 $26 Million - $30.5 Million
107,220 Added 20.75%
624,044 $175 Million
Q4 2020

Feb 09, 2021

BUY
$236.26 - $355.63 $19.2 Million - $29 Million
81,406 Added 18.7%
516,824 $127 Million
Q3 2020

Nov 12, 2020

BUY
$264.77 - $305.71 $13 Million - $15 Million
49,103 Added 12.71%
435,418 $124 Million
Q2 2020

Aug 10, 2020

BUY
$258.66 - $342.55 $9.68 Million - $12.8 Million
37,434 Added 10.73%
386,315 $103 Million
Q1 2020

May 12, 2020

SELL
$268.85 - $341.04 $16.1 Million - $20.5 Million
-60,015 Reduced 14.68%
348,881 $110 Million
Q4 2019

Feb 13, 2020

BUY
$220.06 - $304.07 $10.3 Million - $14.3 Million
46,897 Added 12.96%
408,896 $121 Million
Q3 2019

Nov 08, 2019

BUY
$217.44 - $243.88 $11.3 Million - $12.7 Million
51,931 Added 16.75%
361,999 $84.3 Million
Q2 2019

Aug 07, 2019

BUY
$219.29 - $241.72 $13.2 Million - $14.6 Million
60,339 Added 24.16%
310,068 $72.5 Million
Q1 2019

May 13, 2019

BUY
$216.71 - $338.96 $7.38 Million - $11.5 Million
34,036 Added 15.78%
249,729 $59 Million
Q4 2018

Feb 12, 2019

BUY
$278.5 - $352.75 $2.69 Million - $3.4 Million
9,644 Added 4.68%
215,693 $64.9 Million
Q3 2018

Nov 13, 2018

SELL
$293.51 - $383.83 $2.31 Million - $3.02 Million
-7,859 Reduced 3.67%
206,049 $72.8 Million
Q2 2018

Aug 13, 2018

BUY
$257.52 - $306.91 $2.53 Million - $3.01 Million
9,806 Added 4.8%
213,908 $62.1 Million
Q1 2018

May 11, 2018

SELL
$260.13 - $367.91 $6.19 Million - $8.76 Million
-23,802 Reduced 10.44%
204,102 $55.9 Million
Q4 2017

Feb 12, 2018

SELL
$307.64 - $344.58 $2.33 Million - $2.61 Million
-7,578 Reduced 3.22%
227,904 $72.6 Million
Q3 2017

Nov 09, 2017

SELL
$281.15 - $329.69 $5.99 Million - $7.02 Million
-21,295 Reduced 8.29%
235,482 $73.7 Million
Q2 2017

Aug 11, 2017

BUY
N/A
256,777
256,777 $69.7 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Van Eck Associates Corp Portfolio

Follow Van Eck Associates Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

News

Stay updated on Van Eck Associates Corp with notifications on news.